Fadraciclib, a CDK2/CDK9 inhibitor, shows efficacy in biliary tract cancer and synergistic potential with olaparib and JQ1 based on MCL1 expression
法德拉西利（Fadraciclib）是一种 CDK2/CDK9 抑制剂，在胆道癌中显示出疗效，并且基于 MCL1 表达，与奥拉帕尼（olaparib）和 JQ1 具有协同作用的潜力。
期刊:Cell Communication and Signaling
影响因子:8.9
doi:10.1186/s12964-025-02521-4
Kim, Jae-Min; Nam, Ah-Rong; Oh, Kyoung-Seok; Bang, Ju-Hee; Jeong, Yoojin; Choo, Sea Young; Kim, Hyo Jung; Lee, Su In; Yoon, Jeesun; Kim, Tae-Yong; Oh, Do-Youn
